GGrantIndex
Sort

30,917 grants matching tumor microenvironment

Understanding the Impact of Microscale and Nanoscale Heterogeneity and Resistance

$461,333
Joe W. Gray · Oregon Health & Science University · U54 · FY2020 · CA

Targeting UHRF1 in combinational immunotherapy

$461,315
Xiao-Fan Wang · Duke University · R01 · FY2022 · CA

Optimal control models of epithelial-mesenchymal transition for the design of pancreas cancer combination therapy

$461,276
Matthew J Lazzara · University Of Virginia · U01 · FY2020 · CA

Informatics for Integrative Brain Tumor Whole Slide Analysis

$461,236
Joel H Saltz · Emory University · R01 · FY2012 · LM

Mechanical Stress and Lung Tumor Progression

$461,181
Jeffrey A. Weiss · Utah State Higher Education System--University Of Utah · R01 · FY2025 · CA

Mechanisms of cytokine driven tumor elicited inflammation in colorectal cancer

$461,149
Sergei I Grivennikov · Cedars-Sinai Medical Center · R01 · FY2020 · CA

Mechanisms of cytokine driven tumor elicited inflammation in colorectal cancer

$461,092
Sergei I Grivennikov · Cedars-Sinai Medical Center · R01 · FY2021 · CA

Targeting UHRF1 in combinational immunotherapy

$461,025
Xiao-Fan Wang · Duke University · R01 · FY2023 · CA

Epigenetic Synergy Between DNMT and EZH1/2 Inhibitors for Therapy in Solid Tumors

$460,981
Scott Rothbart · Coriell Institute For Medical Research · P50 · FY2024 · CA

Cell-Selective CpG-STAT3 Inhibitors for Radioimmunotherapy of Malignant Glioma

$460,943
Marcin Kortylewski · Beckman Research Institute/City Of Hope · R01 · FY2020 · CA

Intracellular Trafficking and Signaling Of The B-cell Antigen Receptor

$460,941
Susan Pierce · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI

Tumor Immune MicroEnvironment Facility

$460,935
Wiem Lassoued · Division Of Basic Sciences - Nci · ZIC · FY2021 · CA

Molecular mechanisms and therapeutic principles of VISTA+ triple-negative breast cancers

$460,899
Joshua James Gruber · Ut Southwestern Medical Center · R01 · FY2025 · CA

Proj. 2: Combining immune checkpoint blockade with T cell activation

$460,878
E. Antonio Chiocca · Brigham And Women'S Hospital · P01 · FY2024 · CA

Enhancing Adoptive Immunotherapy Targeting Pediatric High-Grade Gliomas

$460,837
Duane A. Mitchell · University Of Florida · R01 · FY2015 · CA

The role of GPR133 in glioblastoma

$460,820
Dimitris G. Placantonakis · New York University School Of Medicine · R01 · FY2019 · NS

The role of GPR133 in glioblastoma

$460,820
Dimitris G. Placantonakis · New York University School Of Medicine · R01 · FY2020 · NS

Mechanisms of Tumor Cell Dormancy and Tumor Recurrence

$460,765
Jeffrey E Green · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA

Translation of a novel combination therapy approach for non-Hodgkin lymphoma

$460,749
Shruthi Naik · Mayo Clinic Rochester · U01 · FY2025 · CA

Defining and characterizing microenvironmental drivers of disseminated tumor cell dormancy in brain

$460,702
Cyrus M Ghajar · Fred Hutchinson Cancer Center · R01 · FY2024 · CA

Lymph node-targeted codelivery of albumin-binding peptide antigens and di-adjuvant for melanoma combination immunotherapy

$460,692
Guizhi Zhu · Virginia Commonwealth University · R01 · FY2022 · CA

Therapeutic Targeting of Macrophage PI3Kgamma in HNSCC

$460,674
Judith A. Varner · University Of California, San Diego · R01 · FY2019 · CA

An image-guided immunotherapy and hyperthermia delivery device to overcome barriers to tumor immunity for advanced hepatocellular carcinoma

$460,631
Rahul Anil Sheth · University Of Tx Md Anderson Can Ctr · R37 · FY2023 · CA

Regulation of lung cancer growth and metastasis by an actionable driver of vesicle biogenesis in the Golgi

$460,592
Jonathan M Kurie · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA

Dissecting FAK-regulated oncogenic signaling programs in ovarian cancer

$460,555
David D Schlaepfer · University Of California, San Diego · R01 · FY2023 · CA